| IAP |
Drug |
Company |
Mode of action |
Clinical Trial |
Ref. |
| XIAP |
AEG35156 |
Aegera Therapeutics |
Antisense |
Phase 1 |
[118] |
| Embelin |
Small molecule targeting BIR3 domain |
Pre-clinical |
[119,120] |
| Polyphenylureas / Xantags |
Burnham Institute |
Small molecule targeting BIR2 domain |
Pre-clinical |
[121] |
| Arylsulfonamides (TWX006, TWX024) |
Novartis |
Pre-clinical |
[122] |
| Survivin |
LY2181308 |
Eli Lily |
Antisense |
Phase 2 |
[92,93] |
| YM155 |
Astellas Pharma Inc |
Small molecule antagonist |
Phase 2 |
[123] |
| Shepherdin |
Small molecule targeting Hsp90 |
Pre-clinical |
[124,125] |
| AICAR |
Phase II |
[126] |
| Anti-Survivin Ab |
Antibody |
Phase 1 |
[85] |
| cIAPs and XIAP |
TL32711 (Birinapint) Compound A |
TetraLogic Pharma |
Smac mimetic |
Phase 1 /2 |
[76] |
| AEG40826 (HGS1029), |
Aegera Therapeutics |
Phase 1 |
[17] |
| AEG40730 |
Aegera Therapeutics |
Phase 2 |
| Compound 8, BV6, SM-122, SM-164 |
Ascenta Therapeutics |
Pre-clinical |
[75] |
| AT-406 |
Ascenta Therapeutics |
Phase 1 |
[127] |
| Compound 3 |
University of Texas/Joyant |
Phase 1 |
[74] |
| LBW242, LCL-161 |
Novartis |
Phase 1 |
[128] |
| Compound C |
Genentech |
Phase 1 |
[129] |
| Compound 11 |
Pfizer |
Pre-clinical |
[130] |
| JP-1201 |
Pre-clinical |
[115] |
|
